• LAST PRICE
    2.6200
  • TODAY'S CHANGE (%)
    Trending Up0.0700 (2.7451%)
  • Bid / Lots
    2.3900/ 23
  • Ask / Lots
    2.7500/ 30
  • Open / Previous Close
    2.5800 / 2.5500
  • Day Range
    Low 2.5600
    High 2.7100
  • 52 Week Range
    Low 1.5000
    High 10.5300
  • Volume
    7,795
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 2.55
TimeVolumeCWBR
09:37 ET2002.58
09:57 ET5002.59
10:02 ET1002.59
10:18 ET28952.71
10:20 ET1402.64
10:22 ET1902.6424
10:58 ET1002.6711
11:34 ET4502.62
11:36 ET1002.62
12:10 ET1672.6105
12:32 ET1002.59
01:04 ET4002.63
01:54 ET9892.56
03:01 ET1002.6142
04:00 ET2832.62
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCWBR
CohBar Inc
7.4M
-0.7x
---
United StatesATNF
180 Life Sciences Corp
7.6M
-0.4x
---
United StatesBZYR
Burzynski Research Institute Inc
7.6M
-8.3x
---
United StatesXTLB
X T L Biopharmaceuticals Ltd
7.2M
-2.3x
---
United StatesPHIO
Phio Pharmaceuticals Corp
7.0M
-0.6x
---
United StatesCELZ
Creative Medical Technology Holdings Inc
7.5M
-0.3x
---
As of 2023-02-07

Company Information

CohBar, Inc. is a clinical-stage biotechnology company. The Company focuses on developing therapeutics targeting chronic and age-related diseases. It is advancing a pipeline of peptide analogs through varying stages of development, such as CB5138-3 for idiopathic pulmonary fibrosis (IPF); CB4211 for the treatment of non-alcoholic steatohepatitis (NASH) and obesity; and several preclinical and discovery-stage programs. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing, and optimizing analogs of these natural mitochondrial derived peptides (MDPs), as well as developing and conducting screens to identify and characterize the activities of these peptides are referred to its Mito+ platform. It is using its Mito+ platform to identify and develop modified versions of natural peptides called analogs, to treat a range of serious conditions, with a focus on chronic diseases involving inflammation and fibrosis.

Contact Information

Headquarters
1455 Adams Drive, Suite 2050MENLO PARK, CA, United States 94025
Phone
650-446-7888
Fax
302-655-5049

Executives

Independent Chairman of the Board
David Greenwood
Chief Executive Officer, Director
Joseph Sarret
Chief Financial Officer, Treasurer, Secretary
Jeffrey Biunno
Director
Stephanie Tozzo
Independent Director
Albion Fitzgerald

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$7.4M
Revenue (TTM)
$0.00
Shares Outstanding
2.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.91
EPS
$-3.95
Book Value
$8.90
P/E Ratio
-0.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.